Clinical study evaluating serum thymosin β4 levels in 76 NAFLD patients versus 130 healthy controls in an Egyptian cohort. Serum TB4 was significantly altered in NAFLD patients and correlated with disease activity markers. Provides direct clinical evidence for TB4 as a serum NAFLD biomarker—validated in a larger cohort than the later Egyptian NAFLD study (PMID 35436057)—and supports both biomarker and mechanistic roles for TB4 in the progression of fatty liver disease.
Jiang, Yong; Zhang, Ying; Ma, Cui-Hua; Zhang, Zhi-Guang; Li, Man; Ji, Ying-Lan; Qi, Feng-Xiang